Overview
We are engaged in clinical research trials of new therapies for various retinal diseases, particularly macular degeneration and diabetic retinopathy.
Age-Related Macular Degeneration
Anti-Vascular Endothelial Growth Factor
These clinical trials are studying the effect of intraocular injection of different drugs that inhibit new blood vessel growth and leakage in wet AMD.
Eyetech Pharmaceuticals/Pfizer - Macugen
A phase II/III randomized, double-masked, controlled, dose-ranging, multi- center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).
Ongoing - Enrollment Closed
A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).
Ongoing - Enrollment Closed
A Phase II prospective, randomized, double-masked, sham-controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age-related macular degeneration (AMD).
Ongoing - Enrollment Open
Genentech - Lucentis
A phase III, multicenter, randomized, double-masked, active treatment- controlled study of the efficacy and safety of rhuFab (ranibizumab) compared with Verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration.
Ongoing - Enrollment Closed
Reducing the Risk of Developing Wet Age-Related Macular Degeneration in the Second Eye
Alcon - Risk Reduction in Wet Age-Related Macular Degeneration
This study is testing the use of periocular injection of anecortave acetate, and angiostatic steroid, to reduce the chances of developing wet macular degeneration in the second eye of patients with wet AMD.
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients in Patients (Enrolled in Study "A" or Study "B") at Risk for Developing Sight Threatening Choroidal Neovascularization (CNV) Due to Exudative Age Related Macular Degeneration (AMD), Protocol Number C-02-60.
Ongoing - Enrollment Open
Diabetic Retinopathy/Diabetic Macular Edema
Eyetech Pharmaceuticals
A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant macular edema (CSME) involving the center of the macula.
Ongoing - Enrollment Closed
National Eye Institute
Study of Diabetic Retinopathy in the Family Investigation of Nephropathy and Diabetes
Ongoing - Enrollment Open
Diabetic Retinopathy Clinical Research Network (DRCR)
Diabetic Retinopathy Clinical Research Network Protocol 1-A: A pilot study of laser photocoagulation for diabetic macular edema.
Sponsor: JAEB Center
Ongoing - Enrollment Open
Retinal Vein Occlusions
Eyetech Pharmaceuticals
A Phase II randomized, double-masked, multi-center trial, in groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO.
Ongoing - Enrollment Open
National Eye Institute: Standard Care Versus Coricosteroids For Treatment Of Retinal Vein Occlusions
Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Vein Occlusion and One for Branch Retinal Vein Occlusion
Ongoing - Enrollment Open
Allergan
Posurdex - A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-controlled Trial (with six-month Open-Label Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System ) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.
